News
Newron to Present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
ICON Reports First Quarter 2023 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2023.
CEO, Dr
Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a study “Cost-Effectiveness of a
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of LUPKYNIS®
Owens & Minor Announces First Quarter 2023 Earnings Release Date and Conference Call
Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the first quarter of 2023 on Friday, May 5, 2023, before trading begins on the New York Stock Exchange.
The Company will
Charles River Laboratories Launches Next Generation Sequencing Services for Bacterial Identification and Fungal ID
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Accugenix® Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix®
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented two additional posters reporting the latest research updates on CLEC-1 (new myeloid immune checkpoint), from
LivaNova Reports First-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance.
Financial
Premier, Inc. Reports Fiscal-Year 2023 Third-Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 third quarter ended March 31, 2023 and provided
Newron Announces Senior Management Team Changes
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
Sensorion to Host a Symposium during ISIET’s International Symposium on Inner Ear Therapeutics on April 30, 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce it will host a
Agilent to Announce Second-Quarter Fiscal Year 2023 Financial Results May 23
Agilent Technologies Inc. (NYSE: A) will release financial results and hold an earnings conference call for the second quarter of fiscal year 2023 after the stock market closes on Tuesday, May 23
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that Glass Lewis & Co. (“Glass Lewis”), a leading independent proxy advisor, has recommended that Aurinia
Pfizer Declares Second-Quarter 2023 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 second-quarter 2023 dividend on the company’s common stock, payable June 9, 2023, to holders of the Common Stock
Poxel Announces Multiple TWYMEEG® (Imeglimin) Abstracts Accepted for Oral Presentation
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2023, on Thursday, May 4, 2023
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that leading independent proxy advisor Institutional Shareholder Services (“ISS”) has recommended that
OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces three presentations at the American Association for Cancer Research (AACR) Annual Meeting in Orlando
STAAR Surgical to Report First Quarter Results on May 3, 2023
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the first quarter
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial results after the market closes on